Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668248 · ClinicalTrials.gov registry record · NA
Novel Application of Simulation for Providers to Overcome Decisional Gaps in High-risk Prescribing
A NA study of Medication Administered in Error and Antipsychotics and Neuroleptics Toxicity, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT04668248: Completed NA study of Medication Administered in Error and Antipsychotics and Neuroleptics Toxicity, sponsored by Brigham and Women's Hospital.
NCT04668248 is a NA study of Medication Administered in Error and Antipsychotics and Neuroleptics Toxicity that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 47 participants, below the 877-participant average among 3 other Medication Administered in Error trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04668248, a NA study of Medication Administered in Error and Antipsychotics and Neuroleptics Toxicity, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot project aims to reduce the prescribing of high-risk medications, such as antipsychotics and benzodiazepines, to hospitalized older adults. To accomplish this, this project consists of two phases. The purpose is to determine whether a novel simulation-based training program reduces prescribing of suboptimal medications for older adults. A 2-arm pilot randomized controlled trial will be conducted to test a simulation-based, principle-driven intervention targeting high-risk prescribing practices versus control.
Primary Outcome
This will include the number of pills or injection order of high-risk medications (i.e., anti-psychotics, benzodiazepines, and sedative hypnotic "Z-drugs") administered to eligible patients (i.e., those 65 or older not previously on one of these medications)
Conditions Studied
Interventions
- OTHER Simulation
- OTHER Online educational training
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
What the finished NCT04668248 record still lists
NCT04668248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 877-participant average among 3 other Medication Administered in Error trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Medication Administered in Error appearing as the primary indexed condition, and to 2 interventions - of which Simulation is the first listed.
NCT04668248 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04668248 about?
NCT04668248 is a clinical study titled "Novel Application of Simulation for Providers to Overcome Decisional Gaps in High-risk Prescribing". This pilot project aims to reduce the prescribing of high-risk medications, such as antipsychotics and benzodiazepines, to hospitalized older adults. To accomplish this, this project consists of two phases. The purpose is to determine whether a novel simulation-based training program reduces prescri...
What is the current status of trial NCT04668248?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2021-03-29. Estimated completion is 2021-12-31.
What conditions does trial NCT04668248 study?
This clinical trial studies the following conditions: Medication Administered in Error, Antipsychotics and Neuroleptics Toxicity.
What interventions are being tested in trial NCT04668248?
The interventions under investigation include: Simulation (OTHER), Online educational training (OTHER).
Who is sponsoring clinical trial NCT04668248?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04668248 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medication Administered in Error
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI